Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK
Ioanna Vlachaki, Daniela Zinzi, Edel Falla, Theo Mantopoulos, Holly Guy, Jasimran Jandu, Andrew Dodgson
Year of publication: |
2022
|
---|---|
Authors: | Vlachaki, Ioanna ; Zinzi, Daniela ; Falla, Edel ; Mantopoulos, Theo ; Guy, Holly ; Jandu, Jasimran ; Dodgson, Andrew |
Published in: |
The European journal of health economics. - Berlin : Springer, ISSN 1618-7601, ZDB-ID 2011428-X. - Vol. 23.2022, 3, p. 537-549
|
Subject: | Best available treatment | Carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase | Cost-effectiveness | Meropenem-vaborbactam | Arzneimittel | Pharmaceuticals | Kosten-Wirksamkeits-Analyse | Cost-effectiveness analysis | Theorie | Theory | Infektionskrankheit | Infectious disease |
Saved in:
freely available